Topic:

M&A

Latest Headlines

Latest Headlines

Recipharm buys into Italy with $165M CMO deal

Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.

Roche ready to roll on InterMune's lung drug with $8.6B buyout deal

InterMune has already bet a big chunk of money on its idiopathic pulmonary fibrosis drug Esbriet (pirfenidone). Now, Roche is laying $8.3 billion on the table, too. The Swiss drugmaker agreed to pay $74 per share, in cash, for the biotech company, to add the lung treatment to its own respiratory stable.

Roche is buying (again): extends biotech shopping spree with $8.3B InterMune buyout

Roche has won the behind-the-scenes auction for InterMune and its late-stage drug for idiopathic pulmonary fibrosis, announcing Sunday that it is buying up the U.S. biotech for $8.3 billion.

Valeant, Ackman pass threshold to call pivotal Allergan meeting

On Thursday, a judge ruled that an Allergan lawsuit against Valeant wouldn't delay a potential special meeting of Allergan shareholders, at which the Canadian pharma hoped to oust the Botox-maker's board and strike its takeover defenses. The news came not a moment too soon for Valeant, which now says it has successfully rounded up the support needed to call that meeting.

Covidien acquisition of Reverse Medical illustrates vascular device focus

Covidien today announced the acquisition of privately held Reverse Medical, a provider of vascular devices, for an undisclosed sum.

Pfizer-AstraZeneca sequel could hit theaters next week

Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.

2014 has potential to exceed milestone year of 2009 for M&A action

Pharma M&A action so far this year has been intense--so intense that if it keeps up the pace it could match the uber years of 2008 and 2010, maybe even the record year of 2009.

Medtronic shareholders face up to capital gains tax from Covidien merger

Corporate tax inversions, including Medtronic's planned shift to Ireland following its purchase of Covidien, are causing a backlash among some shareholders stuck with a big tax bill becaues of capital gains taxes associated with the deal.

Pfizer eyes Actavis in backup plan to another AstraZeneca bid

Pfizer may not get a great shot at buying AstraZeneca this fall--but it's preparing to give it a try. Meanwhile, Bloomberg reports, the U.S.-based drug giant is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.

Medtronic, Covidien unveil joint integration team

Covidien and Medtronic announced more than 45 people will join a newly created team to tackle integration issues during their merger.